Pediatric data of the usefulness of estimated average glucose (eAG) in glycemic control and cardiovascular risk reduction

The Estimated Average Glucose (eAG) is assumed to provide patients a better understanding of their recent average blood sugar levels comparing to HbA1c, therefore better control their glycemic levels. However, since its inception, debates on its clinical utility have been over several years leading to an unpopular laboratory and clinical practice of adoption; and there is no evidence to support or against the usefulness of eAG in real world medical practice. Data set presented in this article is related to our research paper entitled “Usefulness of Estimated Average Glucose (eAG) in glycemic Control and Cardiovascular Risk Reduction”, available in Clinical Biochemistry [1]. In this article, we compared population lipid and glycemic controls in pediatric diabetic patients of the regional health authority (RHA) zone 1.1 in New Brunswick, Canada, before and after the eAG implementation in January 2010, and with other 7 zones that do not report the parameter. Data (7,355 HbA1c values and 2,062 LDL-c values) was extracted from all pediatric diabetic patients in the Provincial Diabetes Registry from 2008 to 2014. The proportions of patients achieving therapeutic targets (HbA1c<53 mmol/mol (7.0%) and LDL-c<2.6 mmol/L) and the distributions of HbA1c and LDL-c values pre/post the eAG implementation in RHA Zone 1.1 were assessed. Additionally, to investigate whether the glycemic and cholesterol control in pediatric diabetic patients in RHA Zone 1.1 after the implementation of eAG was better than in other zones, we also compared the medians and inter quartile ranges of HbA1c and LDL-c from different zones from 2010 to 2014.